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Abstract
Estimates of cost and cost-effectiveness are typically based on a limited number of small-scale
studies with no investigation of the existence of economies to scale or intra-country variation in
cost and cost-effectiveness. This information gap hinders the efficient allocation of health care
resources and the ability to generalize estimates to other settings. The current study investigates
the intra-country variation in the cost and cost-effectiveness of nationwide school-based treatment
of helminth (worm) infection in Uganda. Programme cost data were collected through semi-
structured interviews with districts officials and from accounting records in six of the 23
intervention districts. Both financial and economic costs were assessed. Costs were estimated on
the basis of cost in US$ per schoolchild treated and an incremental cost effectiveness ratio (cost in
US$ per case of anaemia averted) was used to evaluate programme cost-effectiveness. Sensitivity
analysis was performed to assess the effect of discount rate and drug price. The overall economic
cost per child treated in the six districts was US$ 0.54 and the cost-effectiveness was US$ 3.19 per
case of anaemia averted. Analysis indicated that estimates of both cost and cost-effectiveness
differ markedly with the total number of children which received treatment, indicating economies
of scale. There was also substantial variation between districts in the cost per individual treated
(US$ 0.41-0.91) and cost per anaemia case averted (US$ 1.70-9.51). Independent variables were
shown to be statistically associated with both sets of estimates. This study highlights the potential
bias in transferring data across settings without understanding the nature of observed variations.
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Introduction
Cost-effectiveness analysis has become a principal tool to evaluate health interventions,
guiding health policy in both developed (McDaid et al., 2003) and developing countries
(World Bank, 1993; Jamison et al. 2006). Estimates of cost-effectiveness are typically taken
from a single study or a few small-scale studies in different countries (Walker and Fox-
Rushby, 2000), with no attempt to review the possible variation in estimates. However,
because both intervention costs and effectiveness differ among locations, a single estimate
of cost-effectiveness is unlikely to be universally applicable (Musgrove and Fox-Rushby,
2006). More probable is that costs and cost-effectiveness will vary, even within a single
country. For instance, intra-country variation in costs have been demonstrated in the
delivery of routine immunization in Peru (Walker et al., 2004), antenatal care in Cuba and
Thailand (Hutton et al., 2004), a bednet distribution programme in Malawi (Stevens et al.,
2005) and a lymphatic filariasis elimination programme in Egypt (Ramzy et al. 2005).
Variations in average costs may arise in the short run from differences in the relative costs
of inputs; differences in technical efficiency; or, in the long run, from factors associated with
economies of scale (Folland et al., 2004). Differences may also reflect variation in respect to
the demography and epidemiology of disease, availability of health care resources and
system of health delivery (Drummond and Pang, 2001). Understanding how and why costs
vary can help assess the degree to which cost and cost-effectiveness estimates can be
reliably extrapolated across different settings and also enable health planners and policy
makers discern what drives costs and plan future budgets (O’Brien, 1997; Bryan and Brown
1998; Spath et al., 1999; Drummond et al. 1992; Drummond and Pang, 2001; Walker et al.
2004). This understanding is particularly important for global health programmes which
implement a common health package in a range of settings. For example, a number of
initiatives are now underway which seek to control disease due to a number of tropical
diseases, including those caused by parasitic helminth (worm) infections (Albonico et al.,
2006; Boatin and Richards, 2006; Ottesen, 2006; Fenwick et al., 2006).
The staff of these initiatives, together with national programme staff, also need information
on how costs change as the programmes are gradually scaled-up. In economics, changes in
the level of output may change average costs; as output increases, average costs either
remain constant (constant returns to scale), decrease (economies of scale) or increase
(diseconomies of scale) (Folland et al., 2004). Many studies assume constant returns to scale
and take average costs per recipient and multiply them by projected output levels (e.g.
Fenwick et al., 2005; Brady et al., 2006). In practice however available studies demonstrate
that average costs vary at different levels of output (Over, 1998; Valdmanis et al., 2003;
Mansley et al., 2002; Elbasha and Messonnier, 2004).
There is a clear need for empirical evidence to better understand variations in cost and cost-
effectiveness, particularly in the context of large-scale control programmes. This paper
assesses both variation in costs and cost-effectiveness, and the effect of scaling-up on costs
of a nationwide helminth control programme. The specific aims are to (1) investigate the
intra-country variation in the cost and cost-effectiveness of a national school-based
schistosomiasis and soil-transmitted helminth (STH) control programme in Uganda, (2)
determine the effects of scaling up on costs and cost-effectiveness, and (3) identify the main
determinants of average costs.
Description of the control programme
In 2003, the Ugandan Ministry of Health (MoH) launched its national schistosomiasis and
STH control programme (Kabatereine et al., 2006a,b). Implemented vertically through the
Vector Control Division (VCD) in Kampala, the programme is and aims to provide
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anthelmintic (deworming) treatment to schools and communities at risk of morbidity due to
helminth infection. In brief, the programme comprises the following activities: community
sensitization, training of teachers and community drug distributors (CDDs) and school-based
delivery of two anthelmintic drugs. Mass treatment with praziquantel to treat
schisotosomiasis and with albendazole to treat soil-transmitted helminths was given to all
schools and communities in targeted areas. Treatment in schools is carried out by teachers
and in communities by CDDs. The programme manager and VCD headquarters staff have
overall responsibility for the programme and regularly visit districts to monitor progress.
Implementation of the programme at the district level is undertaken by District Vector
Control Officers (DVCOs) and district health teams.
To help create awareness and political engagement, a series of national workshops were held
in Kampala between 2001 and 2005 (two in 2001, two in 2002 and one each in 2004 and in
2005). The implementation of control began with a pilot phase from April to October 2003
targeting 400,00 people, with one subcounty selected for mass treatment in each of the 18
most affected districts (Kabatereine et al., 2006a). In 2004, the number of sub-counties
targeted in each of the 18 districts was increased and in 2005, the programme was expanded
to include 23 districts, targeting 2.3 million people (Kabatereine et al., 2006b). In each
district, training workshops provided teachers and CDDs with a basic understanding of
schistosomiasis and STH and how to complete record forms and to administer tablets. The
design of training and number of participants varying between districts. Health education
messages were delivered through posters, booklets and audio and film media. All
information, education and communication (IEC) material was translated into various local
languages. Imported drugs were cleared at Entebbe airport by the Uganda National Medical
Stores, who transported them to VCD headquarters. Drugs and IEC material were either
transported to the districts by VCD or collected by the districts during routine visits to
Kampala. Drug registration and treatment included compiling school enrolment data and
community census information to determine the target population and drug needs. The
number of tablets provided to each school was calculated on the basis of treatment registers
completed by head teachers and CCDs. The drugs were delivered to each school by the
DVCOs and were received by the head teacher. Tablets were then administered by teachers
on a specified day in all schools under the supervision of the head teachers and community
health workers. In communities, treatment was provided by CCDs. Praziquantel (25mg/kg)
was administered to individuals on the basis of height, using locally made height poles, and
every individual was given a single dose of albendazole (400mg). All unused tablets were
recovered by DVCOs who also compiled a report of activities.
Data and methods
Only costs associated with school-based treatment are considered here because of the global
focus of helminth control on the school age child (Bundy et al., 2006) and the availability of
detailed effectiveness data for schoolchildren (Kabatereine et al., 2007).
Cost analysis
Cost data were collected retrospectively from the VCD team in Kampala and from six of the
23 intervention districts (Figure 1). Districts were chosen to reflect differences in disease
transmission (Kabatereine et al., 2004) and in socio-economic and health service
infrastructure. Data collection was carried out between February and June 2006. A semi-
structured questionnaire was drafted and was revised and amended during joint discussions
with MoH officials. Data were collected by interviews with district officials using the final
questionnaire and by consultation of the programme accounting system in Kampala.
Documentation related to expenditure had been checked by each district accountant for
accountability and cross-checked by the research team for accuracy.
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The perspective adopted in the evaluation was the government, rather than society since the
costs of accessing treatment are negligible, as children were treated in their own schools.
Both financial and economic costs were estimated. Financial costs represent cash
expenditure paid for the implementation of the intervention on an annual basis. Economic
costs included the opportunity cost of using existing Ministry of Health staff and school
teachers as well as annuitized capital costs, and represent the true cost of any intervention.
Opportunity costs for staff were calculated from salary costs, based on Ugandan civil service
pay scales for 2005. Capital costs were annuitized over the useful life of each item using a
discount rate of 3%, consistent with the recommendations of the World Bank (1993). Such
annuitization enables an equivalent annual cost to be estimated and reflects the value-in-use
of capital items, rather than reflecting when the item was purchased. The assumed useful life
of buildings was 30 years, vehicles 7.5 years, motorcycles 4 years and computers 3 years.
Vehicle running costs also included maintenance and insurance. The purchase, freight and
insurance of drugs was paid in foreign currency (US$). All other costs were paid in Uganda
Shillings (USh) and converted to US dollars using official exchange rates, based average
yearly exchange rate: 2003, 1777 USh = 1 UD$; 2004, 1807 USh; and 2005, 1844 USh
(www.oanda.com/convert/classic). Monetary costs were adjusted for inflation over time
using the Gross Domestic Product (GDP) implicit price deflator (http://ifs.apdi.net/imf/
logon.aspx) and expressed in 2000 prices. Details on the resources employed, their unit costs
and quantities consumed are provided in the appendix. All costs directly related to research
activities were excluded.
The cost data are organized in six main cost centres: (i) programme running costs; (ii)
community awareness; (iii) training; (iv) imported drugs; (v) drug registration and
distribution; and (vi) IEC material. The different cost components of intervention were
identified using an ingredients approach, considering both the number of units and the prices
of units in local currency (Ugandan Shillings). The unit cost data were combined with
numbers treated to calculate, on a district-by-district basis, the average cost per child treated.
The relationship between the cost per child treated and the percentage of overall costs due to
different cost centres and other independent demographic and geographic variables was
assessed using a non-parametric Spearman rank correlation.
Effectiveness
Evidence of the programme effectiveness was measured in terms of anaemia cases averted.
Epidemiological data were collected prospectively through longitudinal surveys conducted
in 30 schools between 2003 and 2005. The details of the sampling strategy, survey design
and procedures are provided elsewhere (Brooker et al., 2004; Kabatereine et al., 2007).
Population-based measures of programme impact included parasitological and
haematological data which were collected from randomly selected schoolchildren who were
followed up over three years. Anaemia is defined as haemoglobin concentration (Hb) <110
g/L. The current analysis focuses on those districts where cost data were collected, thereby
excluding effectiveness data from Arua, Bugiri and Mayunde districts. The number of cases
of anaemia averted was calculated by multiplying the absolute difference in proportion of
anaemia cases averted between 2003 and 2005 by the total number of children treated. This
was calculated on a district-by-district basis, as well as, overall, assuming the mean
difference in proportion of anaemia cases averted among districts.
Cost-effectiveness analysis
The counterfactual is defined as ‘do-nothing’. This is justified on the basis that prior to the
current control programme, no efforts were made to control helminth infection in the
country, with only passive detection of cases in health centres and presumptive treatment,
although in practice, anthelmintic drugs were rarely available. Cost-effectiveness is defined
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in terms of the cost per case of anaemia averted, and cost-effectiveness ratios are based on
annual economic costs.
Sensitivity analysis
Sensitivity analysis allows for uncertainty within the economic evaluation. It shows how
responsive the result is to changes in key economic parameters but also gives an indication
of the robustness of the estimate to changes in unknown variables. Sensitivity analysis was
undertaken to investigate the effect on the results of varying the discount rate (reduced to
1% and increased to 10%), the prices of the drugs (reduced by 10% and 20% to reflect the
use of cheaper drugs in the future) and effectiveness of treatment in reducing the proportion
of anaemia case (reduced by 33% and 50% to reflect differences in the impact of treatment
on anaemia in different transmission settings). One-way scenario sensitivity analysis was
carried out to assess the impact of key variables on estimates of the cost per anaemia case
averted.
Results
Total financial and economic costs
The total financial cost of the intervention in the six districts was estimated at US$ 161,312.
The financial costs per district ranged from US$ 18,015 in Masindi district to US$ 33,809 in
Hoima district. The economic cost of the intervention was calculated by valuing staff time
and annuitizing capital costs to provide an equivalent annual cost. The economic costs of the
intervention in each district are summarized by the major cost centres in Table 1. The total
economic cost was estimated at US$ 218,303: ranging from US$ 25,624 in Masindi district
to US$ 44,958 in Hoima district). In each district, the largest individual cost item was the
purchase of drugs, ranging from 23.1% of total costs in Masindi district in 2003 to 52.1% in
Moyo district in 2005. Community sensitization activities and IEC materials were the next
largest items (Table 1).
Costs per children treated
The overall financial cost per child treated in the six districts was US$ 0.39. The total
economic cost per child treated in the six districts was US$ 0.54, which includes the imputed
value of labour as well as annuitized capital costs. Considerable variation in the economic
costs per child treated existed between districts and between years, ranging from US$ 0.41
to US$ 0.91 (Table 2). The economic delivery cost per child treated (which excludes drug
cost) also varied considerably: US$ 0.19-0.69. The cost per child treated is highly sensitive
to the total number of children treated (Figure 2). Increasing the number of children treated
can significantly decrease the cost per child treated (Figure 2a; Spearman’s rho: -0.93,
p<0.001), suggestive of economies of scale. Similar economies of scale were observed in the
delivery cost per child treated (Figure 2b; Spearman’s rho: -0.93, p<0.001).
In order to investigate possible causes of observed variation in costs, the relationship
between delivery cost per child treated and the percentage of overall costs due to different
cost centres was investigated. Cost per child treated was significantly associated with the
percentage of overall costs due to sensitization and awareness (Spearman’s rho: 0.769,
p=0.0002). The majority of the costs involved here are per diems (allowances) rates paid to
district officials, which ranged from US$ 4.95-15.44, although the correlation between
allowance rates and cost per child treated was non-significant (Spearman’s rho: 0.19,
p=0.444). Differences in demographic and geographic factors, including distance of each
district from Kampala, geographical area and population density of the district, and in
epidemiological factors, such as baseline intensity of infection and reduction in infection
following treatment, were not significantly associated with costs per child treated.
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Cost-effectiveness
Among the 1,455 children monitored for the three-year period, the percentage of anaemic
children, defined as Hb<110 g/L, fell from 35.2% in 2003 to 18.5% in 2005, following three
rounds of treatment. This translates to a 52.5% reduction in the proportion of anaemia cases
within the study population. Table 3 reports the proportion of anaemia cases averted over the
three year period by district. Overall, 0.4 million children were treated at an estimated cost
of US$ 3.19 per case of anaemia averted. Cost-effectiveness ranged from US$ 1.70 in Moyo
district to US$ 9.51 in Masindi district. Cost-effectiveness decreased with increasing cost
per child treated (Figure 3a; Spearman’s rho: 0.940.19, p=0.005) and increased with
increasing difference in the proportion of anaemia as a result of the intervention (Figure 3b;
Spearman’s rho: 1.0, p<0.0001). This suggests that neither costs nor effectiveness are
constant and therefore cost-effectiveness varies between districts. Figure 3c indicates a
negative association between cost-effectiveness and the number of children receiving
treatment (Spearman’s rho: -0.828, p=0.04), suggesting that there are increasing returns to
scale in cost-effectiveness with respect to the target population.
Sensitivity analysis
The sensitivity of cost-effectiveness (cost per anaemia case averted) to variation in key
parameters was explored (Table 4). Varying the discount rate made little difference to the
estimate of cost-effectiveness. Reducing the prices of drugs by 10% and 20% reduced the
cost per anaemia cost averted to US$ 3.07 and US$ 2.94, respectively.
Discussion
The cost of school-based control of helminth infection has been widely documented in a
number of pilot programmes (Holland et al., 1996; Guyatt et al., 1993, 1994; Guyatt, 2003;
Partnership for Child Development, 1998, 1999; Mascie-Taylor et al., 1999). Few studies,
however, have looked at costs of school-based control under nationwide programmatic
conditions (Sinuon et al., 2005; Gabrielli et al., 2006). This current study is the first to
document both the costs and cost-effectiveness of a national school-based control
programme involving mass treatment for schistosomiasis using praziquantel and for
intestinal nematodes using albendazole. The overall economic cost per child treated in the
six districts was US$ 0.54, the overall financial cost per child treated was US$ 0.39, and the
cost-effectiveness was US$ 3.19 per case of anaemia averted.
These estimates fall below the range of estimates from the experience of the Partnership for
Child Development in Africa, where the financial cost per child treated with praziquantel
and albendazole was estimated to be US$ 1.22 and US$ 0.24, respectively in Ghana and US
$ 0.79 and US$ 0.23, respectively in Tanzania (Partnership for Child Development, 1998,
1999). The related economic costs were US$ 2.94 and US$ 0.27 in Ghana and US$ 1.32 and
US$ 0.26 in Tanzania. The programmes in Ghana and Tanzania included prior screening of
urinary schistosomiasis at the school level using a questionnaire about symptoms of urinary
schistosomiasis, administered by teachers, adding to overall costs. Such an approach is not
applicable for intestinal schistosomiasis - the species endemic throughout in Uganda -
because of the non-specific nature of its symptoms, and therefore mass treatment was
provided to all schools in target subcounties. Furthermore, both the praziquantel and
albendazole used in the Ghana and Tanzania programmes were proprietary and not generic
products and therefore costed more than in the Uganda programme, where the drugs used
were generic products (costing US$ 0.20 compared to US$ 0.68 in Ghana and Tanzania).
However, our estimates include start-up costs and central running costs, which were
excluded in the Ghana and Tanzania estimates. In Burkina Faso, a crude macro-costing of
overall costs of a combined school-based and community-based national control programme
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estimated the financial cost per child of providing praziquantel and albendazole to be US$
0.32 (Gabrielli et al., 2006); although this is likely to be an underestimate because of the
methodology adopted.
Regarding cost-effectiveness, Guyatt et al. (2001) estimated that the cost per anaemia
(Hb<110 g/L) case prevented over 15 months as part of the Tanzania programme could be
achieved at a cost of US$ 7.43 using the existing school system to deliver anthlemintics.
This higher estimate is due to the higher costs mentioned above and that the intervention
only reduced anaemia by 25% in Tanzania. In a study on the island of Zanzibar, Stoltzfus et
al. (1998) estimated that the cost per moderate to severe anaemia case (Hb<90 g/L) averted
over one year for thrice-yearly mebendazole treatment was US$ 3.57, increasing to US$
16.30 for a case of severe anaemia averted (< 70 g/L).
Our study showed that estimates of cost and cost-effectiveness differ markedly with the total
number of children treated. Specifically, average costs per child treated ranged from US$
0.91 at an output of 7,161 children treated to US$ 0.41 at an output of 37,032 children
treated. Over the same output range, delivery costs ranged from US$ 0.69 to US$ 0.19. It is
also shown that cost-effectiveness increases with increasing output. Various reasons might
explain the occurrence of these economies of scale. First, a number of the costs are fixed,
and therefore increasing output reduces average fixed costs per child treated. Second, there
is increasing ease, through better organization, learning-by-doing and more efficient
processes, in implementation as the programme expands (Elbasha and Messonnier, 2004). It
is possible that further expansion of the programme into more remote areas may entail
diseconomies of scale due to greater transport costs and stretched administrative structures
and human resources (Johns and Torres, 2005). Economies of scale have previously been
documented for cancer detection programmes in the USA (Mansley et al., 2002), mass polio
immunization campaigns in China (Zhang et al., 1998), vaccination sites in Bangladesh
(Valdmanis et al., 2003), a national insecticide-treated net programme in Malawi (Stevens et
al., 2005) and shopkeeper training programme for improving malaria home management in
Kenya (Goodman et al., 2006). In the Malawian bednet programme, the scale efficiency
saving were mostly related to lowering product or procurement costs (Stevens et al., 2005).
Together with these studies, our findings confirm the assertion of Jabobs and Baladi (1996)
that assuming constant returns to scale are unlikely to be reliable.
This study also highlights the substantial variation between districts in the cost per
individual treated with praziquantel and albendazole and in cost-effectiveness. We found
that the cost per schoolchild treated was lowest (US$ 0.41) in Moyo district and highest (US
$ 0.91) in Masindi district. Cost-effectiveness ranged from US$ 1.70 to US$ 9.51 among
districts. Because the same costing methods were used in each district, we can exclude
methodological inconsistencies as a major source of variation. The results represent a first
initial analysis of why costs and cost-effectiveness vary within a country. In economic
terms, differences in costs may reflect underlying differences in the underlying production
and cost frontiers and in the technical efficiency in delivering the intervention (Folland et
al., 2004). We found that the percentage of total costs attributed to community sensitization
differed across districts and was statistically associated with the delivery cost per child
treated. Differences in these costs were predominantly due to the higher number of
participants, especially supervisors from the district, included in the sensitization, and their
allowances and salary costs. Because district officials are paid an allowance for such
supervision there is an incentive for some district officials to increase the amount of
supervision, possibly leading to inefficiency.
We did not observe that costs varied according to the epidemiology, geography or
demography of the district. Hutton et al. (2004) found that the major determinants of the
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costs of antenatal care in Cuba and Thailand were staffing patterns and productivity, where
productivity was assessed using data envelopment analysis (DEA) (Charnes et al., 1995).
This analytical approach was been employed by Valdmanis et al. (2003) in evaluating
vaccination sites in Bangladesh where they identified levels of output which where technical
inefficient as well as scale inefficient. Unfortunately, the small number of implementation
units (districts) included in the present study precluded the use of DEA and so it was not
possible to identify the optimal average costs and scale of operation to maximise technical
efficiency. The current study needs to be repeated using larger sample sizes to quantitatively
investigate the existence of technical inefficiencies. Further investigation of why costs and
effects vary within different settings and between countries would also allow some
judgement to be made about the relative impact of independent variables on programme
costs and cost-effectiveness in a range of settings, and the extent to which cost estimates can
and cannot be generalised to other settings. To guide this empirical work there is a related
requirement to develop a common analytical framework for assessing cost variation (Hutton
et al., 2004).
There are several qualifications in the present analysis which justify attention. First,
although we have inferred that the reduction in the prevalence of anaemia was due to the
intervention, one could argue that external factors may be responsible for the observed
changes. Cluster-randomized trials are the accepted gold standard for evaluating health
interventions delivered at the community level (Kirkwood et al., 1997). In the Uganda
programme, however, it was not possible to study control cohorts of children because it was
felt that a randomized controlled design, a so-called probability design (Habicht et al,,
1999), would not bear relevance to the operational reality of the national programme and
would be politically difficult to implement and ethically inappropriate. As a result, there is
an opportunity for chance and bias to contribute to the differences observed compared to
randomized controlled trials. However, robust statistical analysis indicated that
improvements in haemoglobin were largest for children who harboured the heaviest
infections at baseline and that observed changes in infection patterns were in accordance
with predictions arising from independently validated mathematical models of transmission
dynamics (Kabatereine et al., 2007).
A second limitation is that the number of anaemia cases averted is an intermediate health
outcome, which does not translate into a universally comparable health outcome measure
such as deaths or disability-adjusted life years (DALYs). However, the basis for converting
observed changes in patterns of helminth infection and nutrition into DALYs remains
controversial (King et al. 2005; Hotez et al., 2006). To date, only one theoretical study has
compared the cost-effectiveness of helminth control in relation to other programmes on the
basis of DALYs (Warren et al., 1993), and this included a number of assumptions which
have been subsequently questioned (Evans and Guyatt, 1995). Estimation of alternative
outcome measures such as quality-adjusted life years (QALYs) remain problematic in a sub-
Sahara African setting, where individuals suffer multiple health insults and are typically
unable to distinguish between conditions (Kirigia, 1998; Nyandieka et al., 2002). A second
alternative outcome measure is the proportion of individuals harbouring a heavy infection
(Guyatt et al., 1994) since morbidity is associated with heavy infection prevalence of heavy
helminth infection. WHO (2002) provides definitions of heavy infection based on the
intensity of infection as assessed by faecal egg counts. However, these units are specific to
individual helminth species, making the definition of a single, multiple-species threshold
impossible. Comparison of the cost-effectiveness of school-based helminth control in
relation to other public health interventions requires a more universal unit. The advantage of
measuring cost-effectiveness in terms of anaemia is that it is an easily assessed outcome,
which has been used to evaluate a number of tropical disease interventions (Stoltzfus et al.,
1998; Guyatt et al., 2001; Wiseman et al. 2003; Baltussen et al. 2004). It is recognised
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however that the use anaemia may miss the more subtle health benefits of deworming such
as improved growth and education (King et al. 2005; Hotez et al., 2006).
There are a number of policy implications arising from this study. First, the analysis presents
costs that are likely to be representative of a full-scale national programme and suggests that
the programme is affordable. In particular, the cost estimates support the conclusions of
earlier studies (PCD, 1998, 1999; Guyatt, 2003), which suggest that regular school-based
delivery of simple and safe health interventions is a relatively low cost approach.
Second, the existence of intra-country variation in costs and variable returns to scale clearly
indicates that comparison of costs and cost-effectiveness across programme settings and
time periods could be misleading unless the effect of differences in input prices and output
are taken into account. This is especially important in relation to forecasting costs and cost-
effectiveness (Mansley et al., 2002). Many estimates of hypothetical public health
programmes assume average cost will remain constant in relation to the population served
(Fenwick et al., 2005; Brady et al., 2006). This assumption is, as indicated here, invalid and
could lead to inaccurate cost projections. A further implication of the existence of
economies of scale identified by Mansley et al. (2002) relates to comparing different
interventions. Given that the cost-effectiveness is dependent on output, it is valid only to
compare different interventions with similar outputs, or undertake some form of analytical
adjustment to empirical estimates (Elbasha and Messonnier, 2004).
Third, the results indicate that substantial variation in intervention costs exist within a single
national programme. As such, it is important to carefully consider which costs can be
reliably extrapolated across different programmes. Further empirical studies coupled with
the development of modelling techniques can inform future extrapolations. Such studies can
also identify potential cost savings and technical efficiencies, thereby inform policy
decisions and promote long-term sustainability of national programmes.
Finally, there is recent interest in the possibility of simultaneously treating a number of
parasitic diseases as part of an integrated control package (Hotez et al., 2006; Lammie et al.,
2006). Adding more treatments to the current programme may yield economies of scope
resulting in lower average costs (Folland et al., 2004). However, this may also cause
diseconomies of scope (increasing average costs), whereby adding more treatments
overloads capacity and the current treatment is delivered less efficiently (Johns and Torres,
2005). This aspect deserves critical attention as integrated programmes are rolled out.
Conclusion
Economic evaluation has become a key criterion relevant for priority setting in health and in
planning health care interventions. The current analysis is the first to document both the cost
and cost-effectiveness of national school-based helminth control and the first to document
the intra-variation in both costs and cost-effectiveness. We report the existence of economies
of scale and intra-country variation in costs and in cost-effectiveness, and present an initial
analysis of the causes of observed variation. The findings highlight the potential bias in
transferring data across settings without understanding the nature of observed variations.
Failure to do so will ultimately hinder the efficient allocation of health care resources.
However, the consistency in the findings suggests that it may be possible to adjust for such
variation in future analysis and the challenge remains to develop a analytical framework for
understanding and assessing the extent and causes of cost variation. More evidence is clearly
necessary on the cost-effectiveness of nationwide control under a range of programmatic
conditions and on the underlying causes of variation in cost and cost-effectiveness.
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Appendix
resources, quantities and unit costs (Table A1)
The resources employed, the quantities consumed and unit costs are described below under
the different cost centres. Many of the costs were divided equally between the school-based
programme and the community-based programme, although a cost analysis is only presented
for school-based treatment.
Programme running costs
The programme has a main office at the VCD headquarters in Kampala, which incurred
expenses such as telephone, stationary, computers and vehicles. An estimate of the
proportion of time staff at VCD in Kampala devoted to the programme. The additional
resources used in making the intervention available were also estimated, including new
capital costs such as vehicles, building space and equipment.
The financial cost of a new building in Kampala used to store drugs and other equipment
and to house some of the programme officers was estimated on the basis of the cost of
constructing and furnishing the building (US$ 87,000), annuitized using an estimated useful
life of 30 years. An estimated 10% to cover annual utilities was included. The building is
shared with the onchocerciasis and filariasis control programmes and therefore it was
assumed that 45% of the building costs were attributable to the current programme. Between
2002 and 2005, five vehicles were purchased by the programme at a total cost of US$
134,183. The costs of these vehicles annuitized over a useful life of 7.5 years and it was
assumed that 70% of costs were attributable to programme activities. Annual expenditure on
services and repairs was assumed to be 10% of annualised capital costs. Allowances of
drivers and staff from the headquarters visiting districts were included in district-level cost
estimates. Fuel costs to each district were calculated using MoH guidelines for distance from
Kampala to specific district capitals. A computer and fax machine were also purchased at a
total cost of US$ 2,245, assuming 100% allocation to the programme and a 3 year useful
life. Annuitized capital costs were allocated equally across the 23 districts, attributing half
the cost to school-based treatment and half to community-based treatment. Each of the
districts was provided with a motorcycle at a cost of US$ 2,899 each, assumed to have a
useful life of 5 years and estimated to have an annuitized cost of US$ 633, and split 50:50
between school- and community-based treatment.
Community sensitization
Prior to treatment, a series of meetings were held with community leaders and school
committee members. The format of these meetings and the number of participants varied
between districts. A mobile film team from MoH headquarters visited each district and
showed a film in several communities to raise awareness about schistosomiasis and soil-
transmitted helminths. The opportunity cost for using existing district health officials was
estimated.
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Training
The costs of the national training workshops were US$ 16,980 in May 2001, US$ 11,285 in
November 2001, US$ 13,500 in June 2002, US$ 26,000 in December 2002, US$ 20,000 in
April 2004 and US$ 22,107 in April 2005. Attended by national staff and district health
staff, the workshops provided general information on schistosomiasis and STH and the
national programme, as well as training on treatment registration and recording and drug
administration. The total cost of these workshops is divided equally among the 26 districts,
allocating half the cost to school-based treatment and half to community-based treatment.
The opportunity cost for using existing district health officials for the training and the time
of teachers was estimated.
In 2003, a training manual was developed by staff from VCD and SCI. The unit cost was
$10.00, and ten copies were provided to each district in 2003; this cost was shared 50:50
between school-based and community-based delivery. At the district-level, the training of
school teachers and community drug distributors included public awareness, drug treatment
and treatment monitoring and record keeping. The expenditure for this training included
trainee transport and lunch allowance, stationary (typically exercise books, pens, marking
tape, permanent markers and flipcharts), district training facilitators per diem, district drivers
per diem and fuel. The estimate of costs also included the per diem and fuel costs of national
staff from Kampala attending the district-level training. The unit cost and quantities of each
cost element varied between districts and had to be estimated separately.
Drug distribution and treatment
Praziquantel tablets were supplied by Shin Pong Pharmaceutical Company (Kyonggi, South
Korea) at a unit price of US$0.072 per 600mg tablet. Assuming 2.5 tablets per child, the
drug cost per child treated was US$0.18. Albendazole tablets (400mg) were supplied by
International Dispensary Association (Amsterdam, Netherlands) at a unit price of US$0.023,
including CIF. The Uganda National Medical Stores cleared the imported drugs and
transported them to VCD headquarters in Kampala at a cost of 5% of the drug price. Drug
distribution and treatment included school, drug delivery, supervision and recording of
treatment, and collection of treatment registers and unused drugs. Per diems or allowances
(which varied between districts) were paid to MoH staff within a district and to community
health workers to perform these activities; however, teachers were not paid. Fuel and
stationary costs were also estimated. The initial cost of locally produced registers to record
treatment was $US 2.53 but this was subsequently reduced to US$ 1.64. In 2003 and 2004
the cost of locally manufactured height poles was $US 1.29; in 2005 modifications of the
pole reduced this cost to $US 0.34. The mean treatment dose per child and adult was
estimated from treatment registers. Based on experience of other programmes (PCD, 1999)
and local experience, the wastage rate of drugs was assumed to be 1%. Where activities
covered both school-based and community-based delivery of treatment, the costs of the
activity were shared 50:50 between the two delivery systems.
Production and distribution of IEC material
Health education messages were delivered through posters, booklets, films and radio shows.
Information, education and communication (IEC) material included posters, leaflets and
question and answer booklets. These were developed in English and then translated into
various local languages by the Health Education department of the Ministry of Health at a
cost of US$ 26,000. This cost was again divided equally among the 26 districts. The
distribution channel for the IEC material was the same as the drugs. In addition, an 18
minute educational video film and a five minute advocacy film was produced locally and
shown widely in each district. During the treatment period, which extended from April to
July, radio talk shows were aired frequently on appropriate local FM stations encouraging
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people to take their drugs. The cost of these shows ranged from US$ 378.45 in Moyo district
to US$ 30.68 in Masindi district. The cost elements under this cost centre were shared in the
proportion 50:50 between school-based treatment and community-based treatment.
Table A1
Unit costs (and where appropriate range) of delivering anthelmintic treatment through
schools in Uganda 2003-2005
Category Input Units Unit cost (US$)
Capital items Building Per building 87,000
Project vehicle Per vehicle 25,000-44,304
Computer Per computer 1,545
Fax machine Per machine 700
Salaries National coordinator Per month 409
National administrator Per month 341
Secretary Per month 157
Driver Per month 63
District VCD officer Per month 262
Health worker Per month 157
Teacher Per month 120
Local leader Per month 60
Allowances VCD (Kampala) supervisor per diem Per day 24.70
VCD (Kampala) driver per diem Per day 12.87-17.90
DVCO per diem Per day 4.95-15.44
Driver per diem Per day 1.98-8.44
Community health worker per diem Per day 2.48-5.63
Training workshop participant Per workshop 1.03-3.96
Vehicle running costs Diesel Per litre 0.77-1.18
Insurance Per day 3.97
Maintenance Per day 8.99
Consumables Training manual Per manual 10
IEC Poster Per poster 0.45
IEC leaflet Per leaflet 0.14
IEC booklet Per booklet 0.37-0.42
Praziquantel Per dose 0.18
Albendazole Per dose 0.023
Treatment register Per register 1.64-2.53
Height pole Per pole 1.29
Modified height pole Per pole 0.34
Other National workshop Per workshop 11,285-26,000
Radio show Per show 30.68-378.45
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Figure 1.
Map of Uganda showing districts selected for cost analysis.
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Figure 2.
(a) The relationship between output (number of children treated) and average costs (cost per
child treated) and (b) the relationship between output (number of children treated) and
delivery cost per child treated in six districts in Uganda, 2003-2005.
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Figure 3.
(a) The relationship between economic cost per child treated and cost-effectiveness (cost per
anaemia case averted); (b) the relationship between effectiveness (proportion of anaemia
cases averted) and cost-effectiveness (cost per anaemia case averted); and (c) the
relationship between total number of schoolchildren treated in each district over the period
2003-2005 and cost-effectiveness (cost per anaemia case averted) in six districts in Uganda.
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Table 2
Estimated district-level economic costs (US$) per child treated by district in Uganda 2003-2005, which
included valuation of staff time using full salary costs and annuitized capital costs. Figures in parenthesis
indicate the estimated delivery cost per child treated (which excludes drug costs).
Area/District 2003 2004 2005
Lake Victoria
 Busia 0.60 (0.38) 0.56 (0.34) 0.44 (0.22)
 Mayuge 0.85 (0.63) 0.44 (0.22) 0.87 (0.66)
Lake Albert
 Hoima 0.50 (0.28) 0.45 (0.23) 0.57 (0.36)
 Masindi 0.91 (0.69) 0.67 (0.45) 0.76 (0.54)
Albert Nile
 Moyo 0.41 (0.19) 0.51 (0.29) 0.48 (0.27)
 Nebbi 0.63 (0.41) 0.51 (0.23) 0.56 (0.35)
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Table 4
Results of one-way sensitivity analysis on the cost per case of anaemia averted of a national school-based
anthelmintic treatment programme in Uganda, 2003-2005
Variation tested Economic cost per anaemia cost averted (US$)
Base case 3.19
Discount rate
 1%
3.18
 10% 3.25
Reduction in drug prices
 10%
3.07
 20% 2.94
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